Cargando…

Foretinib Inhibits Cancer Stemness and Gastric Cancer Cell Proliferation by Decreasing CD44 and c-MET Signaling

PURPOSE: CD44 isoforms are highly expressed in cancer stem cells, initiating tumor growth and sustaining tumor self-renewal. Among these isoforms, CD44 variant 9 (CD44v9) is overexpressed in chronic inflammation-induced cancer. CD44 and the mesenchymal-to-epithelial transition (MET) receptor tyrosin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sohn, Sung-Hwa, Kim, Bohyun, Sul, Hee Jung, Choi, Bo Youn, Kim, Hyeong Su, Zang, Dae Young
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7006849/ https://www.ncbi.nlm.nih.gov/pubmed/32099405 http://dx.doi.org/10.2147/OTT.S226951

Ejemplares similares

Responses to the Tepotinib in Gastric Cancers with MET Amplification or MET Exon 14 Skipping Mutations and High Expression of Both PD-L1 and CD44
por: Sohn, Sung-Hwa, et al.
Publicado: (2022)

INC280 inhibits Wnt/β-catenin and EMT signaling pathways and its induce apoptosis in diffuse gastric cancer positive for c-MET amplification
por: Sohn, Sung-Hwa, et al.
Publicado: (2019)

Tepotinib Inhibits the Epithelial–Mesenchymal Transition and Tumor Growth of Gastric Cancers by Increasing GSK3β, E-Cadherin, and Mucin 5AC and 6 Levels
por: Sohn, Sung-Hwa, et al.
Publicado: (2020)

TRK inhibitors block NFKB and induce NRF2 in TRK fusion-positive colon cancer
por: Sohn, Sung-Hwa, et al.
Publicado: (2021)

RNF43 and PWWP2B inhibit cancer cell proliferation and are predictive or prognostic biomarker for FDA-approved drugs in patients with advanced gastric cancer
por: Sohn, Sung-Hwa, et al.
Publicado: (2021)

Entrectinib Induces Apoptosis and Inhibits the Epithelial–Mesenchymal Transition in Gastric Cancer with NTRK Overexpression
por: Sohn, Sung-Hwa, et al.
Publicado: (2021)

Targeted dual inhibition of c‐Met/VEGFR2 signalling by foretinib improves antitumour effects of nanoparticle paclitaxel in gastric cancer models
por: Grojean, Meghan, et al.
Publicado: (2021)

Foretinib Enhances the Radiosensitivity in Esophageal Squamous Cell Carcinoma by Inhibiting Phosphorylation of c-Met
por: Chen, Guang-Zong, et al.
Publicado: (2017)

Combination effect of lapatinib with foretinib in HER2 and MET co-activated experimental esophageal adenocarcinoma
por: Hassan, Md. Sazzad, et al.
Publicado: (2019)

Combination of EGFR Inhibitor Lapatinib and MET Inhibitor Foretinib Inhibits Migration of Triple Negative Breast Cancer Cell Lines
por: Simiczyjew, Aleksandra, et al.
Publicado: (2018)

Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer
por: Shah, Manish A., et al.
Publicado: (2021)

Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer
por: Shah, Manish A., et al.
Publicado: (2022)

Correction: Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer
Publicado: (2022)

56. Foretinib Enhances Myelination of Neurons in Vitro
por: Mirmoeini, Kaveh, et al.
Publicado: (2023)

Foretinib (GSK1363089) induces p53-dependent apoptosis in endometrial cancer
por: Kogata, Yuhei, et al.
Publicado: (2018)

Foretinib Is Effective against Triple-Negative Breast Cancer Cells MDA-MB-231 In Vitro and In Vivo by Down-Regulating p-MET/HGF Signaling
por: Ji, Xiwei, et al.
Publicado: (2023)

Foretinib inhibits angiogenesis, lymphangiogenesis and tumor growth of pancreatic cancer in vivo by decreasing VEGFR-2/3 and TIE-2 signaling
por: Chen, Hsiu-Mei, et al.
Publicado: (2015)

Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation
por: Fujino, Toshio, et al.
Publicado: (2022)

Combination Foretinib and Anti-PD-1 Antibody Immunotherapy for Colorectal Carcinoma
por: Fu, Yuyin, et al.
Publicado: (2021)

Foretinib mitigates cutaneous nerve fiber loss in experimental diabetic neuropathy
por: Daeschler, Simeon C., et al.
Publicado: (2022)

c-Met recruits ICAM-1 as a coreceptor to compensate for the loss of CD44 in Cd44 null mice
por: Olaku, Vivienne, et al.
Publicado: (2011)

CD44 activation state regulated by the CD44v10 isoform determines breast cancer proliferation
por: Guo, Qian, et al.
Publicado: (2021)

The Role of CD44 in the Pathogenesis, Diagnosis, and Therapy of Gastric Cancer
por: Jang, Byung Ik, et al.
Publicado: (2011)

Gefitinib or lapatinib with foretinib synergistically induce a cytotoxic effect in melanoma cell lines
por: Dratkiewicz, Ewelina, et al.
Publicado: (2018)

RNF43 R117fs mutant positively regulates Wnt/β-catenin signaling by failing to internalize FZD expressed on the cell surface
por: Cho, A-Ri, et al.
Publicado: (2022)

Expression and Significance of CD44, CD47 and c-met in Ovarian Clear Cell Carcinoma
por: Wang, Huimin, et al.
Publicado: (2015)

CD44 Variant 9 Serves as a Poor Prognostic Marker in Early Gastric Cancer, But Not in Advanced Gastric Cancer
por: Go, Se-Il, et al.
Publicado: (2016)

Induction of tumor initiation is dependent on CD44s in c-Met(+) hepatocellular carcinoma
por: Dang, Hien, et al.
Publicado: (2015)

CD44/CD24 Expression in recurrent gastric cancer: a retrospective analysis
por: Yong, Ching-Shya, et al.
Publicado: (2012)

Cancer Stem Cell Markers CD44, CD133 in Primary Gastric Adenocarcinoma
por: Nosrati, Anahita, et al.
Publicado: (2014)

Expression of CD44 Variant Exons 8‐10 in Gastric Cancer
por: Yamaguchi, Akio, et al.
Publicado: (1995)

Downregulation of CD44 reduces doxorubicin resistance of CD44(+)CD24(−) breast cancer cells
por: Van Phuc, Pham, et al.
Publicado: (2011)

CD44 promotes cell proliferation in non-small cell lung cancer
por: Hu, Bo, et al.
Publicado: (2018)

Activation of c-Met and Upregulation of CD44 Expression Are Associated with the Metastatic Phenotype in the Colorectal Cancer Liver Metastasis Model
por: Elliott, Victoria A., et al.
Publicado: (2014)

Mechanisms of Acquired Resistance to Savolitinib, a Selective MET Inhibitor in MET-Amplified Gastric Cancer
por: Frigault, Melanie M., et al.
Publicado: (2020)

The effects of crizotinib in a transgenic Drosophila model expressing the human TPM4-ALK fusion gene or TPM4
por: Kim, Yoo Jin, et al.
Publicado: (2019)

CD44(+) gastric cancer cells with stemness properties are chemoradioresistant and highly invasive
por: SUN, MAO, et al.
Publicado: (2013)

Association of Two CD44 Polymorphisms with Clinical Outcomes of Gastric Cancer Patients
por: Bitaraf, Seyed Mohammadreza, et al.
Publicado: (2018)

CD44 is a prognostic biomarker and correlated with immune infiltrates in gastric cancer
por: Hou, Weiyan, et al.
Publicado: (2022)

CD44v8-10 as a potential theranostic biomarker for targeting disseminated cancer cells in advanced gastric cancer
por: Choi, Eun-Seok, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_hvvgpl8egfbi7kro0cnp84gc7q